NorDiag gets licenses p53 and APC markers:
This article was originally published in Clinica
Bergen, Norway-based NorDiag, part of the Novel Diagnostics group, has formed a licensing agreement with Genzyme Corporation for access to the latter's p53 and APC genes. The additional gene markers will be incorporated into NorDiag's Genefec assay test for the early detection of colon cancer. Genefec is a noninvasive colorectal cancer test that uses faecal samples as the specimen. "These extra markers will further increase our assay's sensitivity, making it an even better tool for both diagnostic and public screening programmes," said NorDiag's chairman, Christian Horn.
You may also be interested in...
A collaboration between Novo and Fauna will look at animal hibernation and genetic sequencing for hints toward novel therapies for obesity. Pfizer will use Insilico’s machine learning technology in target validation.
The introduction of gene therapies has been the highest-profile new modality to reach the market, but new RNA-based therapeutics hold significant potential and could be more accessible for patients. Scrip reviews the leading drug developers in this space.